235 related articles for article (PubMed ID: 33887472)
1. An update on recent randomized clinical trials in systemic sclerosis.
Boleto G; Avouac J; Allanore Y
Joint Bone Spine; 2021 Oct; 88(5):105184. PubMed ID: 33887472
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
Yamasaki Y; Kuwana M
Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
[TBL] [Abstract][Full Text] [Related]
3. The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease.
Boleto G; Avouac J; Allanore Y
Ther Adv Musculoskelet Dis; 2022; 14():1759720X211066686. PubMed ID: 35111241
[TBL] [Abstract][Full Text] [Related]
4. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.
Hoffmann-Vold AM; Brunborg C; Airò P; Ananyeva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Valentini G; Kowal-Bielecka O; Allanore Y; Distler O;
Chest; 2023 Mar; 163(3):586-598. PubMed ID: 36244404
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies.
Lescoat A; Roofeh D; Kuwana M; Lafyatis R; Allanore Y; Khanna D
Clin Rev Allergy Immunol; 2023 Jun; 64(3):239-261. PubMed ID: 34468946
[TBL] [Abstract][Full Text] [Related]
6. Current advances in the treatment of systemic sclerosis.
Bukiri H; Volkmann ER
Curr Opin Pharmacol; 2022 Jun; 64():102211. PubMed ID: 35447517
[TBL] [Abstract][Full Text] [Related]
7. An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years.
Campochiaro C; Allanore Y
Arthritis Res Ther; 2021 Jun; 23(1):155. PubMed ID: 34074331
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.
Highland KB; Distler O; Kuwana M; Allanore Y; Assassi S; Azuma A; Bourdin A; Denton CP; Distler JHW; Hoffmann-Vold AM; Khanna D; Mayes MD; Raghu G; Vonk MC; Gahlemann M; Clerisme-Beaty E; Girard M; Stowasser S; Zoz D; Maher TM;
Lancet Respir Med; 2021 Jan; 9(1):96-106. PubMed ID: 33412120
[TBL] [Abstract][Full Text] [Related]
9. Antifibrotics in systemic sclerosis.
Martin-Lopez M; Carreira PE
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101671. PubMed ID: 33839046
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
11. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
Volkmann ER; Tashkin DP
Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196
[TBL] [Abstract][Full Text] [Related]
13. Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.
Zhao M; Wu J; Wu H; Sawalha AH; Lu Q
Clin Rev Allergy Immunol; 2022 Apr; 62(2):273-291. PubMed ID: 33449302
[TBL] [Abstract][Full Text] [Related]
14. [How do I treat interstitial lung disease in systemic sclerosis?].
Riemekasten G
Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
[TBL] [Abstract][Full Text] [Related]
15. Treatment of systemic sclerosis.
Thoreau B; Chaigne B; Renaud A; Mouthon L
Presse Med; 2021 Apr; 50(1):104088. PubMed ID: 34718109
[TBL] [Abstract][Full Text] [Related]
16. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of systemic sclerosis-associated interstitial lung disease].
Prasse A; Bonella F; Müller-Ladner U; Witte T; Hunzelmann N; Distler J
Z Rheumatol; 2020 Apr; 79(3):294-303. PubMed ID: 31754786
[TBL] [Abstract][Full Text] [Related]
18. Targeting Costimulatory Pathways in Systemic Sclerosis.
Boleto G; Allanore Y; Avouac J
Front Immunol; 2018; 9():2998. PubMed ID: 30619351
[TBL] [Abstract][Full Text] [Related]
19. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
McMahan ZH; Volkmann ER
Expert Opin Pharmacother; 2020 Nov; 21(16):2041-2056. PubMed ID: 32674612
[TBL] [Abstract][Full Text] [Related]
20. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
Khanna D; Brown KK; Clements PJ; Elashoff R; Furst DE; Goldin J; Seibold JR; Silver RM; Tashkin DP; Wells AU
Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S55-62. PubMed ID: 20576216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]